Objective: Animal studies suggest that left ventricular hypertrophy might be associated with insulin resistance and alterations in glucose transporters. We have previously demonstrated myocardial insulin resistance in patients with post-ischemic heart failure. The aim was to investigate whether myocardial insulin resistance could be demonstrated in human cardiac hypertrophy in the absence of hypertension, diabetes and coronary artery disease. Methods: Eleven normotensive nondiabetic patients with cardiac hypertrophy due to aortic stenosis and angiographically normal coronary arteries were compared to 11 normal volunteers. Myocardial glucose uptake (MGU) 18 was measured with positron emission tomography and [ F]2-fluoro-2-deoxy-D-glucose during fasting (low insulinemia) or during euglycemic-hyperinsulinemic clamp (physiologic hyperinsulinemia). Myocardial biopsies were obtained in order to investigate changes in insulin-independent (GLUT-1) and insulin-dependent (GLUT-4) glucose transporters. Results: During fasting, plasma insulin (761 vs. 661 mU / l) and MGU (0.1260.05 vs. 0.1160.04 mmol / min / g) were comparable in patients and controls. By contrast, during clamp, MGU was markedly reduced in patients (0.4860.02 vs. 0.7060.03 mmol / min / g, p,0.01) despite similar plasma insulin levels (9566 vs. 7966 mU / l). A decreased GLUT-4 / GLUT-1 ratio was shown by Western blot analysis in patients. Conclusions: Insulin resistance seems to be a feature of the hypertrophied heart even in the absence of hypertension, coronary artery disease and diabetes and may be explained, at least in part, by abnormalities in glucose transporters.
Introduction
heart failure [2] . These myocardial regions, remote from the infarct, are likely to undergo compensatory hyperWhole body insulin resistance, mainly due to a detrophy [3] . On the other hand, in patients with type 1 creased responsiveness to insulin of skeletal muscle [1] , diabetes, peripheral (skeletal muscle) insulin resistance is has been demonstrated to be associated with systemic not accompanied by a reduced cardiac FDG uptake [4, 5] . conditions such as diabetes (both type 1 and type 2), Likewise, in young subjects with mild hypertension and no hypertension and coronary artery disease [1] . More recentcardiac hypertrophy, Nuutila et al. [6] could show skeletal ly, the non-invasive measurement of myocardial uptake of but not cardiac insulin resistance. 18 the glucose analogue [ F] 2-fluoro-2-deoxy-D-glucose Insulin promotes glucose uptake and decreases the (FDG) by positron emission tomography (PET), has made utilisation of free fatty acids by the human heart [7] [8] [9] . it possible to assess the presence of cardiac insulin Glucose is a particularly important substrate for the heart. resistance in humans. We have previously reported that It is more efficient than other substrates in terms of oxygen insulin resistance is present in the non-infarcted myocarconsumption (more ATP is synthesized per mole of oxygen dium of patients with previous myocardial infarction and consumed) and its uptake is increased in myocardial ischemia [10, 11] . In addition, glucose seems to be important for the production of ATP for ion channels and oxaloacetate, thus replenishing Krebs cycle intermediates time of cardiac transplantation. The investigation conforms [14] .
with the principles outlined in the Declaration of Helsinki. Glucose enters the cell using specific transporters [15] . There are five facilitative glucose transporters, named 2.2. Study population GLUT-1 to GLUT-5. Of these, only GLUT-1 and GLUT-4 are present in the heart. Immunofluorescence has demon-2.2.1. PET strated the presence of both on cardiac myocytes [16] . The GLUT-1 isoform, located mainly in the sarcolemmal 2.2.1.1. Patients The patient population consisted of 11 membrane, is thought to be involved in glucose transport normotensive, nondiabetic patients (ten men, aged 6362 in the basal metabolic state. Under such conditions, less years) with pure aortic stenosis and with normal or nonthan 1% of GLUT-4 (the insulin-responsive isoform) is significantly diseased coronary arteries, who were on the located in the sarcolemma [17] . After insulin stimulation, waiting list for valve replacement. All patients were in however, glucose transport is accelerated by translocating NYHA class II and no attempt was made to standardize GLUT-4 from an intracellular pool to the T-tubule and medical therapy. Three patients were on diuretics, one was sarcolemmal membrane [17, 18] . GLUT-4 levels are deon ACE inhibitors, one was on digitalis, one was on creased in adipose tissue in diabetic patients [19, 20] , but calcium antagonists and one was on nitrates. Before the probably not in skeletal muscle [18] . However, it has been PET scan, all patients were studied by echocardiography, reported that GLUT-4 translocation is diminished in the according to the guidelines of the American Society of skeletal muscle of diabetic patients [21] . Much less is Echocardiography (Esaote Biomedica SIM 7000 CFM known about GLUT-4 in the insulin-resistant heart. We echograph). The posterior and septal wall thickness were have previously shown that a decreased expression of measured in M-mode in the left parasternal projection (at cardiac GLUT-4 mRNA accompanies insulin resistance in end diastole). Since these measurements never differed by the hypertrophied heart of the spontaneously hypertensive more than 1 mm, thus excluding asymmetric hypertrophy, rat [22] . In this model, increased basal deoxyglucose only their average thickness is reported in Section 3. uptake and a reduced response to insulin could be demonstrated [22] . In a different model of cardiac hypertrophy in 2.2.1.2. Controls The results of the PET studies in the rat (aortic banding), a decreased ratio of GLUT-4 to patients were compared with those obtained in 11 healthy GLUT-1 mRNA expression has been reported [23] .
male volunteers (aged 4762 years, p,0.05 vs. patients) The purpose of the present study was to establish if matched for body mass index. All had a negative history myocardial insulin resistance is a feature of cardiac for coronary artery disease, normal physical examination, hypertrophy in the absence of systemic conditions that are resting 12 lead electrocardiogram and echocardiogram and known to be associated with a reduced response to this a treadmill exercise test (Bruce protocol) negative for hormone (diabetes, hypertension, coronary artery disease). myocardial ischemia at high workload. Myocardial glucose uptake was estimated using PET in patients with pure aortic stenosis. Furthermore, alterations 2.3. Cardiac biopsies in the expression of glucose transporters, as a possible molecular basis for insulin resistance, were investigated in 2.3.1. Patients cardiac biopsies.
Cardiac biopsies were obtained from four of the aortic stenosis patients (all males, age 5761 years) studied by PET, at the time of aortic valve replacement. In a separate experiment, biopsies were also obtained from five ex-2. Methods planted hearts of patients with end stage heart failure (all males, age 4561 years). Three of these explanted hearts 2.1. Study protocol were from patients with non-ischemic cardiomyopathy and two were from patients with severe coronary artery dis-PET was used to measure myocardial blood flow and ease. FDG uptake at two different levels of plasma insulin: a very low one corresponding to fasting conditions and a 2.3.2. Controls level .ten times higher during hyperinsulinemic Cardiac biopsies were obtained from four donor hearts, euglycemic clamp. Five patients and five controls were at the time of heart transplant. The donors were also all studied during fasting; six patients and six controls were males and aged 3264 years ( p,0.05 vs. patients). studied during hyperinsulinemic euglycemic clamp. The expression of the glucose transporters GLUT-1 and GLUT-2.4. Hyperinsulinemic euglycemic clamp 4 was measured by Western blot analysis in cardiac biopsies from the patients with aortic stenosis. Additional Before the PET scan, a 20-G polyethylene cannula was biopsies were obtained from failing and donor hearts at the inserted in a superficial forearm vein for infusion of glucose and insulin, as described by DeFronzo et al. [24] , was then obtained by multiplying regional influx rates by in order to obtain a near-steady state at physiological the plasma concentration of cold glucose, assuming a concentration of glucose and at plasma insulin values lumped constant of one, and by dividing the product by the similar to those of the post-prandial state. A second corresponding tissue fraction. This last step was performed cannula was threaded retrogradely into a superficial vein of in order to correct for partial volume effect. A conversion the wrist or hand that had been arterialized using a heating for millilitres to grams of perfusable tissue was made by pad set at 508C. At time zero, a primed-constant insulin dividing the flow and metabolic data by the tissue density
infusion (40 mU min m of body surface area) was (1.04 g / ml). Thus, MGU is expressed as mmol min per started. The body surface area was calculated from the g of water perfusable tissue. formula of Du Bois and Du Bois [25] . The prime consisted of four times the final constant rate for the first 4 min, 2.6. Western blots followed by two times the constant rate for 3 min. Four min into the insulin infusion, an exogenous D-glucose All cardiac biopsies were transmural, taken from the left 21 infusion was started at an initial rate of 1.5 mg min per ventricle in an area with no macroscopic signs of fibrosis. kg of body weight. The plasma glucose concentration in
The biopsies from the explanted hearts were cut with a arterialized blood was measured at baseline and then every scalpel. The biopsies from the donor hearts and patients 5 min during the clamp. The glucose infusion rate was undergoing valve replacement were taken using a Tru-cut adjusted according to the change in plasma glucose during (Baxter) biopsy needle and were of smaller dimensions the preceding 5 min. Samples for insulin assay were taken (around 30 mg). The tissue was immediately frozen in from the arterialized vein at 20, 40 and 60 min during the liquid nitrogen and then stored at 2708C. At the time of clamp.
analysis, the samples were pulverized on dry ice with a Glucose was measured with an automatic analyser mortar and pestle, then 100 ml of sample buffer were (2300Stat, Yellow Spring, USA) which required around 30 added to the pulverized tissue. The sample buffer cons per measurement (this is essential during the clamp tained 62.5 mM Tris, 10% glycerol, 2% sodium dodecyl because the rate of infusion has to be adjusted as quickly sulfate (SDS), 2 mM EDTA (all from Sigma) plus the as possible). Insulin was measured in the Endocrinology following protease inhibitors: 1 mg / ml AEBSF, 10 mg / ml Laboratory of Hammersmith Hospital using an immuno-E64, 1 mg / ml pepstatin (all from Boehringer Mannheim). radiometric assay.
After the addition, the tubes were quickly frozen in liquid Under the near-steady-state conditions of euglycemic nitrogen, then boiled and vortex-mixed repeatedly until the hyperinsulinemia prevailing during the second hour of an tissue appeared to be completely solubilized. After 5 min insulin clamp, the exogenous glucose infusion rate equals centrifugation at the maximum speed on an Eppendorf the total amount of glucose metabolized by all tissues and, bench top centrifuge, the supernatant was isolated, 10 ml therefore, is an index of whole-body insulin sensitivity were used for the protein assay and the rest was frozen in
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(expressed in mmol min per kg of body weight). liquid nitrogen and kept at 2708C. The protein content was measured using the assay of Lowry et al. [28] . For 2.5. PET scanning and data analysis electrophoresis, b-mercaptoethanol (3% final) was added to a volume of sample equivalent to 30 mg of protein and PET scanning was carried out in all subjects, as previthen volumes were equalized with sample buffer conously reported [2] . Briefly, the optimal imaging position taining bromophenol blue. Western blotting was performed was determined using a 5-min rectilinear scan and a according to standard procedures [29] . The same filter was 20-min transmission scan was then performed. The blood then probed with two antibodies: anti-GLUT-4 (rabbit show that the expected band (at 50 kilodaltons) was absent analyses were performed using the ANALYZE (Version if the primary antibody was omitted. Immunodetection was 3.0, Biodynamics Research Unit, Mayo foundation, Rochperformed with the ECL system (Amersham). After each ester, MN, USA) and the MATLAB (The MathWorks Inc., immunodetection, the filter was stripped using a 30-min Natick, MA, USA) software packages, respectively. Carincubation in stripping buffer (100 mM b-mercapdiac images were resliced in the short axis view. Tissue toethanol, 2% SDS, 62.5 mM Tris, pH 6.7) and two FDG time-activity curves were analysed by using the washing in phosphate-buffered saline (PBS)-Tween at linearized approach proposed by Patlak et al. [27] for room temperature. The efficiency of stripping was checked irreversible processes. Myocardial glucose uptake (MGU) by reprobing in the absence of primary antibody. The Table 1 intensity of the bands on the autoradiography film were (mmol min g ) considered to be statistically significant.
Myocardial glucose uptake was decreased in patients with aortic stenosis during clamp but not during fasting, while there was no difference in myocardial blood flow in either condition.
Results
Comparing fasting to clamp, there were significant ( p,0.01) differences in myocardial glucose uptake but not in blood flow.
Characteristics of the study population
The body mass index (weight / height [2] ) was 2561 related to whole-body glucose utilization (r50.70, p, 2 2 kg / m in controls and 2761 kg / m in patients ( p5NS).
0.01). The left ventricular wall thickness was 1060.3 mm in controls and 1660.8 mm in patients ( p,0.01). There was 3.3. Glucose transporters no difference in left ventricular wall thickness between patients studied during fasting and during clamp (1661
In the patients with cardiac hypertrophy and aortic mm in the fasting state and 1761.4 mm in the clamped stenosis, the GLUT-4 / GLUT-1 ratio was decreased comstate, p5NS). There were no significant differences bepared to controls (1.260.2 vs. 2.360.2, p50.009). The tween patients and controls in systolic blood pressure GLUT-4 / GLUT-1 ratio was equally decreased in the (12663 mmHg in controls vs. 12664 mmHg in patients), explanted hearts of the patients with heart failure diastolic blood pressure (7563 mmHg in controls vs.
(1.260.1) compared to controls (2.660.3; p50.002) (Fig.  7462 mmHg in patients) and heart rate (6462 bpm in 2). When GLUT-1 and GLUT-4 were expressed as a ratio controls vs. 7164 bpm in patients). The baseline plasma to total protein (in arbitrary density units), the changes glucose concentration was 5.060.2 mM in controls, and were not significant. In patients with aortic stenosis, 4.660.2 mM in patients ( p5NS). During clamp, plasma GLUT-4 was 1.660.3 vs. 2.360.7 in controls and GLUT-1 glucose levels were 6.060.4 and 5.560.2 mM ( p5NS) in was 1.360.3 vs. 1.060.4 in controls. In the explanted controls and patients, respectively. Plasma insulin was hearts of patients with heart failure, GLUT-4 was 1.960.3 761 and 661 mU/l ( p5NS) during fasting and 7966 and vs. 2.660.4 in controls and GLUT-1 was 1.560.4 vs. 9566 mU/l ( p5NS) during clamp, in controls and 1.060.4 in controls. The cause of heart failure did not patients, respectively. The glucose metabolized by the seem to influence the GLUT-4 / GLUT-1 ratio, which was whole body during the last 60 min of the clamp study was 1.360.1 in the three patients with heart failure due to min kg in patients ( p,0.01). patients with heart failure due to coronary heart disease. (Table 1) There was no difference amongst the four groups in 4. Discussion terms of myocardial blood flow rates. There was also no difference in glucose uptake between patients and controls
Myocardial blood flow and glucose uptake
The results obtained in patients with aortic stenosis are during fasting. By contrast, myocardial glucose uptake similar to those we have previously reported in the nonduring clamp was 31% lower in patients. Thus, a 13-fold infarcted myocardium of patients with post-ischemic heart increase in plasma insulin could increase glucose uptake failure [2] and suggest that insulin resistance accompanies by 6.4-fold in controls but only four-fold in patients (Fig. cardiac hypertrophy per se, even in the absence of cor-1). During clamp, cardiac glucose uptake was linearly onary artery disease, diabetes and / or hypertension. 
4.1.
Glucose transporters myocardial ischemia causes translocation of GLUT-4 to the plasma membrane of cardiac myocytes, leading to We found a reduced GLUT-4 / GLUT-1 protein ratio in increased glucose uptake. GLUT-4 depletion could therehearts from patients with end-stage heart failure and in fore limit glucose availability under conditions of hypoxia those with aortic stenosis and we hypothesize that this is a and contribute to myocardial dysfunction. On the other possible molecular basis for the cardiac insulin resistance hand, it is well known that cardiac hypertrophy is associshown by PET. This is also consistent with previous ated with the reappearance of a pattern of gene expression reports of lowered GLUT-4 / GLUT-1 mRNA ratio in that is present in the fetal and newborn heart [35] . The animal models of cardiac hypertrophy [22, 23] . Interestingfetal rat heart has less GLUT-4 and more GLUT-1 than the ly, transgenic mice lacking GLUT-4 expression have adult [36, 37] and our results are in line with the concept of cardiac hypertrophy and a decreased life span [33] , raising re-expression of fetal genes in cardiac hypertrophy. Our the possibility that alterations of glucose metabolism might finding that comparable reductions in the GLUT-4 / GLUTcontribute to and not simply be a consequence of cardiac 1 ratio could be demonstrated in biopsies from patients disease. Furthermore, Sun et al. [34] have shown that with cardiac diseases of different severity and etiology suggests that this might be part of a general response of the myocardium to insult. Similar cardiac isoform switches have been reported for several other proteins, including myosin heavy chain [38] , Na-K-ATPase [39] and creatine kinase [40].
Myocardial blood flow and glucose uptake
Changes in blood flow could affect glucose uptake [41], but our PET measurements do not show any significant effect of insulin on myocardial blood flow during hy- hyperinsulinemia has no effect on coronary blood flow in man [8, 43] or in dogs when physiological doses of insulin difference in glucose uptake between high and low insulin were applied [44] .
concentrations), but could be due to a decrease in GLUT4, The FDG-PET results obtained during fasting, with low an increase in GLUT1 or to both. Changes in GLUT1 and plasma insulin, are different from those reported by several GLUT4 expressed as a ratio to total protein were not in vitro animal studies, both by us and by others (e.g.
significant, but, as mentioned above, these measurements [22, 45] ), where deoxyglucose uptake in the absence of can be considered less reliable than the ratio of the two insulin was shown to be higher in hypertrophied hearts transporters. In fact, Western blots from cardiac biopsies compared to controls. No other human studies of myocarare often quantified as a ratio of two proteins [59] [60] [61] [62] . For dial glucose uptake in global cardiac hypertrophy have ethical reasons, we could obtain only very limited amounts been published. An in vivo NMR animal study [46] has of tissue from donor hearts and from the hearts of patients also reported an increase in deoxyglucose-6-phosphate undergoing valve replacement, therefore, we were unable accumulation in hypertrophied hearts, in the presence of to investigate this point further. However, several authors low circulating insulin values. A dog model of hypertrophy have quantified their glucose transporter measurements as secondary to aortic constriction was employed. A possible a ratio of the two transporters [23, 63, 64] . reason for the different results obtained in man is the It must also be noted that our control group was presence of generalized metabolic alterations that occur in composed of younger individuals compared to the patient patients with heart failure [47] , especially an increase in group. Indeed, in human biopsies studies using donor circulating free fatty acids, since substrate competition hearts as a control group, an age difference is difficult to regulates cardiac glucose uptake [48, 49] . Alterations in avoid. However, although insulin resistance does increase fatty acid levels were however not present in the experiwith age, the age-related changes are very gradual and are ment of Zhang et al. [46] and this might explain why their only minimal between the age groups that we have studied results differed from those we report in man.
[65]. The results of our study are consistent with those of PET allows for attenuation correction of annihilation Maki et al. [50] in patients with coronary artery disease photons, thus enabling the accurate measurement of absoand demonstrate that, in the human heart in vivo, the lute radioactivity concentration in tissues [66] . In the case increase of glucose uptake in response to insulin is much of FDG measurements, however, there are some assumphigher than that in isolated perfused hearts [45, [51] [52] [53] . A tions that we have discussed in detail previously [2] . possible explanation for this difference could be that in Briefly, in order to account for differences in affinity vivo insulin-stimulated myocardial glucose uptake is not between FDG and glucose, both for glucose transporters only due to stimulation of GLUT-4 translocation, but also and hexokinase, the estimate of glucose uptake obtained to a decrease in circulating fatty acids [8, 54] . Furthermore, from FDG-PET is normally divided by the so-called the possible limitations [55] inherent with the use of FDG lumped constant [67] [68] [69] . However, studies in isolated rat for the quantitation of myocardial glucose uptake, which hearts have shown that the lumped constant might vary are discussed below, are more serious when different under different experimental conditions [55] . Therefore, it metabolic states are compared. has been recommended that PET studies of FDG uptake in Several medications are known to affect whole body the heart should be performed under controlled metabolic insulin resistance. ACE-inhibitors are known to improve conditions [55, 70] , as those employed in the present study. insulin sensitivity, while other drugs (e.g. diuretics) might It is worth noting that the difference in myocardial glucose worsen it [56] . It might be an objective for future studies to uptake between fasting and euglycemic clamp estimated elucidate the effects of ACE-inhibitors on cardiac insulin with FDG-PET is very similar to that measured in humans resistance.
during simultaneous arterial and great cardiac vein catheterization [8] .
Possible limitations
Heart failure and hypertrophy are accompanied by an 5. Conclusions increase in extracellular collagen deposition [57, 58] . Therefore, normalizing the Western blot results by total
The response of glucose uptake to insulin in the protein might be inappropriate. The choice of an internal hypertrophied human heart is reduced and this reduction is control is also difficult, since it implies that the control independent of myocardial blood flow and predisposing protein is known not to be altered. Although the GLUT-4 / conditions (hypertension, coronary artery disease, dia-GLUT-1 ratio provides a relative measurement, this has a betes). A lower GLUT-4 / GLUT-1 ratio is a possible clear physiological meaning and has the additional advanmolecular basis for this decreased responsiveness. It tage of correcting for possible variations in the handling of remains to be seen if interventions that are known to the samples or in the efficiency of protein transfer during improve whole body insulin resistance might have an the blotting procedure. Any change in this ratio will effect on cardiac insulin resistance and the progression to influence glucose responsiveness to insulin (that is, the heart failure.
